<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82776">
  <stage>Registered</stage>
  <submitdate>1/05/2008</submitdate>
  <approvaldate>2/05/2008</approvaldate>
  <actrnumber>ACTRN12608000229370</actrnumber>
  <trial_identification>
    <studytitle>2008 Weight Loss, Protein and Bone Density study</studytitle>
    <scientifictitle>A randomised study to investigate the effect of high and normal protein content in weight loss diets on bone density in overweight post menopausal women.</scientifictitle>
    <utrn />
    <trialacronym>BD</trialacronym>
    <secondaryid>KV56C issued by the Commonwealth Scientific Industrial Research Organisation (CSIRO)</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obesity</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A 104 week weight loss study of either:
A high protein diet (35% of calories as protein), low saturated fat (&lt;10%), low total fat (&lt;30%), OR
A normal protein diet with a protein level of 15-20% of calories, low saturated fat (&lt;10%), low total fat (&lt;30%). Both diets will contain 5000-6000KJ</interventions>
    <comparator>Normal protein (15-20% of energy) energy restricted diet.</comparator>
    <control>Active</control>
    <interventioncode>Lifestyle</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>weight, DEXA (dual energy x-ray absoptiometry), blood tests including vitamin D</outcome>
      <timepoint>baseline, 3 months, 6 months, 12 months and 24 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>24hour urinary urea, creatinine, calcium, sodium, phosphate.
Fasting urine pH, calcium, creatinine, sodium, phosphate.</outcome>
      <timepoint>baseline, 3 months, 6 months, 12 months and 24 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria> Female, post menopausal
 Aged between 40-70 years  
 Body Mass Index (BMI) greater than 27, but a maximum weight of 140kg
 Participants must understand the procedures involved and agree to participate in the study by giving full informed, written consent</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria> Body mass index (BMI) less than 27
 Taking antiresorptive agents including Hormone Replacement Therapy
 Vitamin D and/or parathyroid hormone (PTH) and/or serum calcium levels outside the normal range when tested at baseline. If vitamin D is less than 60 and PTH is normal participants will continue in the study but if PTH is also elevated then the participant will be withdrawn and referred to their GP for active treatment.
 Taking agents affecting calcium and bone metabolism such as calcium supplements, steroids or diuretics.
 Bone density in the osteoporotic density range (total hip 2 SD below normal) or a history of low trauma peripheral or spinal fracture (with density &lt;1 SD below normal) as assessed at the baseline examination.
 Have a malignancy, or a history of metabolic disease such as liver, renal, unstable cardiovascular, respiratory or gastrointestinal disease.
 Have high uncontrolled hypertension (resting recumbent Blood Pressure &gt;160/100 mmHg). Once controlled on medication the participant can enter the study
 History of heavy alcohol consumption (&gt; 5 standard drinks/day) 
 Unwilling to be randomized to either trial group
 Extended absences due to travel or other commitments
 Unable to comprehend or cope with study requirements
 At the commencement of the study bone density at the hip, spine and forearm will be measured. Those women in the osteoporotic density range (very low bone density ) at the first examination will not be eligible to participate but  will be referred back to their general practitioner for specific treatment. Those with osteopenia (moderately low bone density) and no fractures will be able to continue in the study if they wish.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation was concealed when it was done by central randomisation by computer</concealment>
    <sequence>Random allocation using computer software "Clinstat"</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>14/04/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>CSIRO Human Nutrition</primarysponsorname>
    <primarysponsoraddress>Gate 13
Kintore Avenue
Adelaide SA 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>CSIRO Human Nutrition</fundingname>
      <fundingaddress>Gate 13
Kintore Avenue
Adelaide SA 5000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>06/23</hrec>
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>CSIRO Human Research Ethics Committee</ethicname>
      <ethicaddress>Gate 13
Kintore Avenue
Adelaide SA 5000</ethicaddress>
      <ethicapprovaldate>19/02/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Jennifer Keogh</name>
      <address>CSIRO Human Nutrition
Gate 13
Kintore Avenue
Adelaide  SA  5000</address>
      <phone>+61 8303 8907</phone>
      <fax>+61 83038899</fax>
      <email>jennifer.keogh@csiro.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Anne McGuffin</name>
      <address>CSIRO Human Nutrition
Gate 13
Kintore Avenue
Adelaide  SA  5000</address>
      <phone>+61 83038988</phone>
      <fax>+61 83038899</fax>
      <email>anne.mcguffin@csiro.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Jennifer Keogh</name>
      <address>CSIRO Human Nutrition
Gate 13
Kintore Avenue
Adelaide  SA  5000</address>
      <phone>+61 8303 8907</phone>
      <fax>+61 83038899</fax>
      <email>jennifer.keogh@csiro.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>